膀胱癌疾病监测中FGFR3和PIK3CA热点突变的液体活检分析
本研究开发了尿液和血浆的微滴式数字PCR检测方法,用于FGFR3和PIK3CA突变膀胱癌患者的疾病监测。在非肌层浸润性膀胱癌队列中,连续尿液上清高肿瘤DNA水平与后续疾病进展相关(p=0.003);在根治性膀胱切除队列中,血浆高肿瘤DNA水平与复发相关(p=0.016)。尿液与血浆肿瘤DNA水平呈正相关(相关系数0.6)。
要点
- 非肌层浸润性膀胱癌患者连续尿液上清高肿瘤DNA水平与后续疾病进展相关(p=0.003)。
- 根治性膀胱切除患者血浆高肿瘤DNA水平与复发相关(p=0.016)。
- 尿液和血浆肿瘤DNA水平呈正相关(相关系数0.6)。
核心结论
- 尿液和血浆中FGFR3和PIK3CA突变DNA水平升高提示膀胱癌后续进展和转移。
研究设计与样本
- 开发微滴式数字PCR检测方法,筛选两个患者队列肿瘤DNA中的FGFR3和PIK3CA热点突变。
- 一个队列包括363例非肌层浸润性膀胱癌患者,另一个队列包括468例接受根治性膀胱切除的膀胱癌患者。
- 随后用微滴式数字PCR检测携带突变患者的尿液上清(非肌层浸润性膀胱癌n=216,根治性膀胱切除n=27)和血浆样本(非肌层浸润性膀胱癌n=39,根治性膀胱切除n=27)。
- 评估无进展生存期、无复发生存期和总生存期,采用Fisher精确检验、Wilcoxon秩和检验和Cox回归分析。
主要发现
- 非肌层浸润性膀胱癌患者中36%(129/363)携带至少一个FGFR3或PIK3CA突变,根治性膀胱切除患者中11%(44/403)携带至少一个FGFR3或PIK3CA突变。
- 非肌层浸润性膀胱癌队列连续尿液上清DNA检测显示,高肿瘤DNA水平与后续疾病进展相关(p=0.003)。
- 根治性膀胱切除队列血浆样本中高肿瘤DNA水平与复发相关(p=0.016)。
- 尿液与血浆肿瘤DNA水平呈正相关(相关系数0.6)。
局限性
- 回顾性研究设计是本研究局限性之一。
- 可用于分析的血浆体积少是本研究局限性之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease surveillance in patients with bladder cancer is important for early diagnosis of progression and metastasis and for optimised treatment. OBJECTIVE: To develop urine and plasma assays for disease surveillance for patients with FGFR3 and PIK3CA tumour mutations. DESIGN, SETTING, AND PARTICIPANTS: Droplet digital polymerase chain reaction (ddPCR) assays were developed and tumour DNA from two patient cohorts was screened for FGFR3 and PIK3CA hotspot mutations. One cohort included 363 patients with non-muscle-invasive bladder cancer (NMIBC). The other cohort included 468 patients with bladder cancer undergoing radical cystectomy (Cx). Urine supernatants (NMIBC n=216, Cx n=27) and plasma samples (NMIBC n=39, Cx n=27) from patients harbouring mutations were subsequently screened using ddPCR assays. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival, recurrence-free survival, and overall survival were measured. Fisher's exact test, the Wilcoxon rank-sum test and Cox regression analysis were applied. RESULTS AND LIMITATIONS: In total, 36% of the NMIBC patients (129/363) and 11% of the Cx patients (44/403) harboured at least one FGFR3 or PIK3CA mutation. Screening of DNA from serial urine supernatants from the NMIBC cohort revealed that high levels of tumour DNA (tDNA) were associated with later disease progression in NMIBC (p=0.003). Furthermore, high levels of tDNA in plasma samples were associated with recurrence in the Cx cohort (p=0.016). A positive correlation between tDNA levels in urine and plasma was observed (correlation coefficient 0.6). The retrospective study design and low volumes of plasma available for analysis were limitations of the study. CONCLUSIONS: Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer. PATIENT SUMMARY: Urine and plasma from patients with bladder cancer may be monitored for diagnosis of progression and metastasis using mutation assays.
引用
- Christensen E, Birkenkamp-Demtröder K, Nordentoft I, et al. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Eur Urol. 2017. PMID: 28069289. doi:10.1016/j.eururo.2016.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。